Rajni Agarwal

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Rajni Agarwal sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials none currently recruiting 1 completed upper half by trial count

Rajni Agarwal: 1 sponsored US clinical trial, none currently recruiting.

Rajni Agarwal sponsors 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 1 completed. The most-studied condition in this pipeline is Malignant Diseases, with 1 trials.

Mid-pack sponsor footprint

Rajni Agarwal is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Indexed trials (enrollment closed)

1 total, page 1 of 1

COMPLETED NA

CD34+ Cell Enriched and T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Mismatched Related Donors or Borderline Organ Function

NCT02162511

Therapeutic Areas

Malignant Diseases 1
Non Malignant Diseases 1

How the Rajni Agarwal archive is shaped

1 indexed studies, none listed as recruiting (0% open); 1 completed (100%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Malignant Diseases (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Rajni Agarwal: archived-pipeline peers nationwide

Peers matched on 1 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Rajni Agarwal sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60% Total trials Recruiting share Rajni Agarwal1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health10xBio22nd Century Group23andMe3-C Institute for Social Development
Rajni Agarwal sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Rajni Agarwal sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Rajni Agarwal page

1 registered trials is a research-attention snapshot, not an endorsement of Rajni Agarwal or any single study.

  • None of Rajni Agarwal's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Malignant Diseases is the condition Rajni Agarwal studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Malignant Diseases trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Rajni Agarwal pipeline card: 1 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.